The global North America point-of-care molecular testing for infectious diseases market is expected to reach US$ 44.59 billion in 2031 from US$ 19.21 billion in 2023. The market is estimated to grow with a CAGR of 11.1% from 2023 to 2031. Research and development continue to play a pivotal role in the evolution of this market. Investment in R&D activities by public and private entities has...